Down -30% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)Zacks Investment Research • 03/23/23
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial ResultsGlobeNewsWire • 03/14/23
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/21/22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial ResultsGlobeNewsWire • 11/10/22
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology DayGlobeNewsWire • 11/07/22
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601GlobeNewsWire • 10/20/22
Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia ResearchGlobeNewsWire • 10/19/22
MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 09/26/22
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional SharesGlobeNewsWire • 09/16/22
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich's Ataxia PatientsGlobeNewsWire • 09/14/22
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial ResultsGlobeNewsWire • 08/11/22
Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain DisordersGlobeNewsWire • 07/28/22
Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and ChloroplastsGlobeNewsWire • 06/28/22
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson's Disease and Movement Disorders CongressGlobeNewsWire • 05/19/22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial ResultsGlobeNewsWire • 05/12/22
Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)Zacks Investment Research • 04/13/22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial ResultsGlobeNewsWire • 03/25/22